Nguyen, R, Fiest, KM, McChesney, J, et al. The international incidence of traumatic brain injury: a systematic review and meta-analysis. Can J Neurol Sci. 2016;43(6):774–85.
Rusnak, M. Traumatic brain injury: giving voice to a silent epidemic. Nat Rev Neurol. 2013;9(4):186–7.
Selassie, AW, Zaloshnja, E, Langlois, JA, Miller, T, Jones, P, Steiner, C. Incidence of long-term disability following traumatic brain injury hospitalization, United States, 2003. J Head Trauma Rehabil. 2008;23(2):123–31.
Osier, ND, Dixon, CE. Catecholaminergic based therapies for functional recovery after TBI. Brain Res. 2016;1640(Pt A):15–35.
Yue, JK, Burke, JF, Upadhyayula, PS, et al. Selective serotonin reuptake inhibitors for treating neurocognitive and neuropsychiatric disorders following traumatic brain injury: an evaluation of current evidence. Brain Sci. 2017;7(12):1–26.
Chen, YH, Huang, EY, Kuo, TT, Miller, J, Chiang, YH, Hoffer, BJ. Impact of traumatic brain injury on dopaminergic transmission. Cell Transplant. 2017;26(7):1156–68.
Shin, SS, Dixon, CE. Alterations in cholinergic pathways and therapeutic strategies targeting cholinergic system after traumatic brain injury. J Neurotrauma. 2015;32(19):1429–40.
Abe, K, Shimada, R, Okada, Y, Kibayashi, K. Traumatic brain injury decreases serotonin transporter expression in the rat cerebrum. Neurol Res. 2016;38(4):358–63.
Kosari-Nasab, M, Shokouhi, G, Azarfarin, M, BannazadehAmirkhiz, M, Mesgari Abbasi, M, Salari, A-A. Serotonin 5-HT1A receptors modulate depression-related symptoms following mild traumatic brain injury in male adult mice. Metab Brain Dis. 2019;34(2):575–82.
Saija, A, Hayes, RL, Lyeth, BG, Edward Dixon, C, Yamamoto, T, Robinson, SE. The effect of concussive head injury on central cholinergic neurons. Brain Res. 1988;452(1–2):303–11.
Massucci, JL, Kline, AE, Ma, X, Zafonte, RD, Dixon, CE. Time dependent alterations in dopamine tissue levels and metabolism after experimental traumatic brain injury in rats. Neurosci Lett. 2004;372(1–2):127–31.
Huger, F, Patrick, G. Effect of concussive head injury on central catecholamine levels and synthesis rates in rat brain regions. J Neurochem. 1979;33(1):89–95.
Dunn-Meynell, AA, Hassanain, M, Levin, BE. Norepinephrine and traumatic brain injury: a possible role in post-traumatic edema. Brain Res. 1998;800(2):245–52.
Iverson, GL, Keene, CD, Perry, G, Castellani, RJ. The need to separate chronic traumatic encephalopathy neuropathology from clinical features. J Alzheimer’s Dis. 2018;61(1):17–28.
Schwab, N, Hazrati, LN. Assessing the limitations and biases in the current understanding of chronic traumatic encephalopathy. J Alzheimer’s Dis. 2018;64(4):1067–76.
McKee, AC, Cairns, NJ, Dickson, DW, et al. The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy. Acta Neuropathol. 2016;131(1):75–86.
Neurobehavioral Guidelines Working G, Warden, DL, Gordon, B, et al. Guidelines for the pharmacologic treatment of neurobehavioral sequelae of traumatic brain injury. J Neurochem. 2006;23(10):1468–501.
Park, E, Bell, JD, Baker, AJ. Traumatic brain injury: can the consequences be stopped? CMAJ. 2008;178(9):1163–70.
Broshek, DK, De Marco, AP, Freeman, JR. A review of post-concussion syndrome and psychological factors associated with concussion. Brain Inj. 2015;29(2):228–37.
Blennow, K, Brody, DL, Kochanek, PM, et al. Traumatic brain injuries. Nat Rev Dis Primers. 2016;2:16084.
Simon, DW, McGeachy, MJ, Bayir, H, Clark, RSB, Loane, DJ, Kochanek, PM. The far-reaching scope of neuroinflammation after traumatic brain injury. Nat Rev Neurol. 2017;13(9):572.
Kokiko-Cochran, ON, Godbout, JP. The inflammatory continuum of traumatic brain injury and Alzheimer’s disease. Front Immunol. 2018;9:672.
Reus, GZ, Fries, GR, Stertz, L, et al. The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders. Neuroscience 2015;300:141–54.
Hong, H, Kim, BS, Im, HI. Pathophysiological role of neuroinflammation in neurodegenerative diseases and psychiatric disorders. Int Neurourol J. 2016;20(Suppl 1):S2–7.
Bergold, PJ. Treatment of traumatic brain injury with anti-inflammatory drugs. Exp Neurol. 2016;275 (Pt 3):367–80.
Zurier, RB, Burstein, SH. Cannabinoids, inflammation, and fibrosis. FASEB J. 2016;30(11):3682–89.
Katz, PS, Sulzer, JK, Impastato, RA, Teng, SX, Rogers, EK, Molina, PE. Endocannabinoid degradation inhibition improves neurobehavioral function, blood-brain barrier integrity, and neuroinflammation following mild traumatic brain injury. J Neurotrauma. 2015;32(5):297–306.
De Guzman, E, Ament, A. Neurobehavioral management of traumatic brain injury in the critical care setting: an update. Crit Care Clin. 2017;33(3):423–40.
Abou El Fadl, MH, O’Phelan, KH. Management of traumatic brain injury: an update. Neurosurg Clin North Am. 2018;29(2):213–21.
Devane, WA, Hanus, L, Breuer, A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258(5090):1946–49.
Reggio, PH. Endocannabinoid binding to the cannabinoid receptors: what is known and what remains unknown. Curr Med Chem. 2010;17(14):1468–86.
Herkenham, M, Lynn, AB, Johnson, MR, Melvin, LS, de Costa, BR, Rice, KC. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci. 1991;11(2):563–83.
Schurman, LD, Lichtman, AH. Endocannabinoids: a promising impact for traumatic brain injury. Front Pharmacol. 2017;8:69.
Mechoulam, R, Panikashvili, D, Shohami, E. Cannabinoids and brain injury: therapeutic implications. Trends Mol Med. 2002;8(2):58–61.
Shohami, E, Gallily, R, Mechoulam, R, Bass, R, Ben-Hur, T. Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant. J Neuroimmunol. 1997;72(2):169–77.
Turna, J, Patterson, B, Van Ameringen, M. Is cannabis treatment for anxiety, mood, and related disorders ready for prime time? Depress Anxiety. 2017;34(11):1006–17.
Degenhardt, L, Hall, W. Cannabis and psychosis. Curr Psychiatry Rep. 2002;4(3):191–96.
Andreasson, S, Allebeck, P, Rydberg, U. Schizophrenia in users and nonusers of cannabis. a longitudinal study in Stockholm County. Acta Psychiatr Scand. 1989;79(5):505–10.
Cannabis, psychosis and schizophrenia: unravelling a complex interaction. Addict. 2017;112(9):1653–57.
Arseneault, L, Cannon, M, Poulton, R, Murray, R, Caspi, A, Moffitt, TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ. 2002;325(7374):1212–13.
Di Forti, M, Sallis, H, Allegri, F, et al. Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull. 2014;40(6):1509–17.
Zammit, S, Allebeck, P, Andreasson, S, Lundberg, I, Lewis, G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ. 2002;325(7374):1199.
Marconi, A, Di Forti, M, Lewis, CM, Murray, RM, Vassos, E. Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull. 2016;42(5):1262–69.
Gibbs, M, Winsper, C, Marwaha, S, Gilbert, E, Broome, M, Singh, SP. Cannabis use and mania symptoms: a systematic review and meta-analysis. J Affect Disord. 2015;171:39–47.
Lev-Ran, S, Roerecke, M, Le Foll, B, George, TP, McKenzie, K, Rehm, J. The association between cannabis use and depression: a systematic review and meta-analysis of longitudinal studies. Psychol. Med. 2014;44(4):797–810.
Gruber, AJ, Pope, HG , Jr., Brown, ME. Do patients use marijuana as an antidepressant? Depression. 1996;4(2):77–80.
Karniol, IG, Shirakawa, I, Kasinski, N, Pfeferman, A, Carlini, EA. Cannabidiol interferes with the effects of Δ9-tetrahydrocannabinol in man. Eur J Pharmacol [Internet]. 1974;28(1):172–77.
Hser, YI, Mooney, LJ, Huang, D, et al. Reductions in cannabis use are associated with improvements in anxiety, depression, and sleep quality, but not quality of life. J Subst Abuse Treat. 2017;81:53–58.
Ablon, SL, Goodwin, FK. High frequency of dysphoric reactions to tetrahydrocannabinol among depressed patients. Am J Psychiatry. 1974;131(4):448–53.
Zuardi, A, Shirakawa, I, Finkelfarb, E, Karniol, IG. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacol. 1982;76:245–50.
Greer, GR, Grob, CS, Halberstadt, AL. PTSD symptom reports of patients evaluated for the New Mexico Medical Cannabis Program. J Psychoact Drugs. 2014;46(1):73–77.
Mizrachi Zer-Aviv, T, Segev, A, Akirav, I. Cannabinoids and post-traumatic stress disorder: clinical and preclinical evidence for treatment and prevention. Behav Pharmacol. 2016;27(7):561–69.
O’Neil, ME, Nugent, SM, Morasco, BJ, et al. Benefits and harms of plant-based cannabis for posttraumatic stress disorder: a systematic review. Ann Internal Med. 2017;167(5):332–40.
Steenkamp, MM, Blessing, EM, Galatzer-Levy, IR, Hollahan, LC, Anderson, WT. Marijuana and other cannabinoids as a treatment for posttraumatic stress disorder: a literature review. Depress Anxiety. 2017;34(3):207–16.
Medical Association C. Government of Canada-task force on Marijuana legalization and regulation CMA submission [Internet]. 2016.
Fontes, MA, Bolla, KI, Cunha, PJ et al. Cannabis use before age 15 and subsequent executive functioning. Br J Psychiatry. 2011;198(6):442–47.
Volkow, ND, Baler, RD, Compton, WM, Weiss, SR. Adverse health effects of marijuana use. N Engl J Med. 2014;370(23):2219–27.
Anstey, KJ, Butterworth, P, Jorm, AF, Christensen, H, Rodgers, B, Windsor, TD. A population survey found an association between self-reports of traumatic brain injury and increased psychiatric symptoms. J Clin Epidemiol. 2004;57(11):1202–09.
Jorge, RE, Robinson, RG, Moser, D, Tateno, A, Crespo-Facorro, B, Arndt, S. Major depression following traumatic brain injury. Arch Gen Psychiatry. 2004;61(1):42–50.
Guskiewicz, KM, Mihalik, JP, Shankar, V, et al. Measurement of head impacts in collegiate football players: relationship between head impact biomechanics and acute clinical outcome after concussion. Neurosurgery. 2007;61(6):1244–52; discussion 52-3.
Silver, JM, McAllister, TW, Arciniegas, DB. Depression and cognitive complaints following mild traumatic brain injury. Am J Psychiatry. 2009;166(6):653–61.
Koponen, S, Taiminen, T, Portin, R, et al. Axis I and II psychiatric disorders after traumatic brain injury: a 30-year follow-up study. Am J Psychiatry. 2002;159(8):1315–21.
Kennedy, E, Heron, J, Munafo, M. Substance use, criminal behaviour and psychiatric symptoms following childhood traumatic brain injury: findings from the ALSPAC cohort. Eur Child Adolesc Psychiatry. 2017;26(10):1197–206.
Walker, R, Cole, JE, Logan, TK, Corrigan, JD. Screening substance abuse treatment clients for traumatic brain injury: prevalence and characteristics. J Head Trauma Rehabil. 2007;22(6):360–67.
Allen, S, Stewart, SH, Cusimano, M, Asbridge, M. Examining the relationship between traumatic brain injury and substance use outcomes in the Canadian population. Subst Use Misuse. 2016;51(12):1577–86.
Ilie, G, Adlaf, EM, Mann, RE, Ialomiteanu, A, Hamilton, H, Rehm, J, et al. Associations between a history of traumatic brain injuries and current cigarette smoking, substance use, and elevated psychological distress in a population sample of Canadian adults. J Neurotrauma. 2015;32(14):1130–34.
Ilie, G, Mann, RE, Hamilton, H, et al. Substance use and related harms among adolescents with and without traumatic brain injury. J Head Trauma Rehabil. 2015;30(5):293–301.
Cicerone, K, Levin, H, Malec, J, Stuss, D, Whyte, J. Cognitive rehabilitation interventions for executive function: moving from bench to bedside in patients with traumatic brain injury. J CognNeurosci. 2006;18(7):1212–22.
Payne, HC. Traumatic brain injury, depression and cannabis use – assessing their effects on a cognitive performance. Brain Inj. 2000;14(5):479–89.
Rabner, J, Gottlieb, S, Lazdowsky, L, LeBel, A. Psychosis following traumatic brain injury and cannabis use in late adolescence. Am J Addict. 2016;25(2):91–3.
Soler, JM, Muller, HA, Trautlein, JJ, Donovan, JW. Posttraumatic aneurysms of the hand. JACEP. 1979;8(6):232–34.
Jain, SS, A.S. Frontal lobe abnormality and psychosis in traumatic brain injury and cannabis use. ASEAN J Psychiatry. 2017;18(1):95–98.
Wilson, JR. Blast-traumatic brain injury (TBI) with post-traumatic stress disorder (PTSD): a treatable condition? Psychol Cogn Sci Open J. 2017;3(4):19–22.
Hunt, C, Guo, M, Michalak, A, et al. Can early life experiences affect cannabis use following a concussion? A survey of patients attending a tertiary care clinic. Poster session presented at International Brain Association, 13th World Congress on Brian Injury. Toronto, ON: St. Michael’s Hospital Head Injury Clinic, University of Toronto; 2019 March 13–16.
Brandt, A, Rehm, J, Lev-Ran, S. Clinical correlates of cannabis use among individuals with attention deficit hyperactivity disorder. J NervMent Dis. 2018;206(9):726–32.
Fergusson, DM, Boden, JM. Cannabis use and adult ADHD symptoms. Drug Alcohol Depend. 2008;95(1–2):90–96.
Nugent, SM, Morasco, BJ, O’Neil, ME, et al. The effects of Cannabis among adults with chronic pain and an overview of general harms: a systematic review. Ann Internal Med. 2017;167(5):319–31.
Deshpande, A, Mailis-Gagnon, A, Zoheiry, N, Lakha, SF. Efficacy and adverse effects of medical marijuana for chronic noncancer pain: systematic review of randomized controlled trials. Can Fam Physician. 2015;61(8):e372–81.
Mucke, M, Phillips, T, Radbruch, L, Petzke, F, Hauser, W. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2018;3:CD012182.